Table 3b.

Revised primary analysis model augmented to include an additional rate correction term as baseline-value x visit to determine whether baseline differences in severity or other characteristics account for differences seen for Comparison C at week 78 in primary and principal secondary outcomes. The baseline-value was either continuous or categorical depending on the nature of the variable

			Comparison C
	Baseline value used as rate correction term		100 mg twice a day as add-on (n = 297)	Difference for 100 mg twice a day as monotherapy (n = 76)	p value
ADAS-cog	ADAS-cog	Mean	6.93	–2.66	0.0058
		95% CI	5.85, 8.01	–4.55, –0.77
	APOE ɛ4	Mean	6.83	–3.98	0.0002
		95% CI	5.56, 8.10	–6.08, –1.88
	Vascular burden	Mean	7.23	–4.06	0.0001
		95% CI	6.07, 8.39	–6.06, –2.06
	Hippocampal volume	Mean	7.15	–3.73	0.0003
		95% CI	5.99, 8.31	–5.74, –1.72
	Temporo-parietal volume	Mean	7.21	–3.64	0.0002
		95% CI	6.08, 8.33	–5.59, –1.69
	Temporal lobe 18F-FDG-PET SUVR	Mean	6.95	–2.92	0.0036
		95% CI	5.83, 8.07	–4.89, –0.96
ADCS-ADL	ADCS-ADL	Mean	–9.96	4.44	0.0007
		95% CI	–11.45, –8.47	1.87, 7.00
	APOE ɛ4	Mean	–9.54	5.29	0.0001
		95% CI	–11.17, –7.90	2.61, 7.96
	Vascular burden	Mean	–9.97	5.29	0.0001
		95% CI	–11.48, –8.46	2.72, 7.87
	Hippocampal volume	Mean	–9.85	4.53	0.0006
		95% CI	–11.34, –8.35	1.95, 7.11
	Temporo-parietal volume	Mean	–9.37	4.56	0.0004
		95% CI	–11.41, –8.45	2.02, 7.09
	Temporal lobe 18F-FDG-PET SUVR	Mean	–9.68	4.19	0.0014
		95% CI	–11.16, –8.20	1.62, 6.77
LVV	LVV	Mean	7.72	–1.93	0.0002
		95% CI	7.10, 8.33	–2.94, –0.92
	APOE ɛ4	Mean	7.41	–2.97	<0.0001
		95% CI	6.66, 8.16	–4.13, –1.81
	Vascular burden	Mean	7.74	–3.21	<0.0001
		95% CI	7.03, 8.46	–4.35, –2.07
	Hippocampal volume	Mean	7.69	–2.94	<0.0001
		95% CI	6.98, 8.40	–4.09, –1.79
	Temporo-parietal volume	Mean	7.71	–3.05	<0.0001
		95% CI	7.00, 8.42	–4.19, –1.91
	Temporal lobe 18F-FDG-PET SUVR	Mean	7.53	–2.25	0.0001
		95% CI	6.86, 8.21	–3.36, –1.14